Significant Ownership of Affinity Asset Advisors, LLC

Signature - Title
/s/ Andrew Weinstein - Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Affinity Asset Advisors, LLC.

Notify me when Affinity Asset Advisors, LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Affinity Asset Advisors, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
IBIO iBio, Inc. Common Stock, par value $0.001 per share 10% $4,627,194 +$424,252 2,401,616 +10% Affinity Asset Advisors, LLC 22 Jan 2026
NXTC NextCure, Inc. Common Stock, $0.001 par value per share 10% $4,375,018 +$1,966,899 348,607 +82% Affinity Asset Advisors, LLC 22 Jan 2026
VTYX Ventyx Bioscience, Inc. Common Stock, $0.0001 par value per share 9% $58,381,906 +$21,744,625 6,465,041 +59% Affinity Asset Advisors, LLC 22 Jan 2026
OVID Ovid Therapeutics Inc. Common Stock, par value $0.001 per share 9% $19,803,141 12,149,166 0% Affinity Asset Advisors, LLC 22 Jan 2026
STRO Sutro Biopharma, Inc. Common Stock, $0.001 par value per share 8.8% $8,444,817 748,382 Affinity Asset Advisors, LLC 22 Jan 2026
KPTI Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value per share 8.6% $12,870,974 +$7,880,460 1,713,092 +158% Affinity Asset Advisors, LLC 22 Jan 2026
STRO SUTRO BIOPHARMA, INC. Common Stock, par value $0.001 per share 7.8% $5,717,348 6,583,772 Affinity Healthcare Fund, LP 16 Oct 2025
LXEO Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share 7.1% $51,813,451 +$9,589,340 5,217,660 +23% Affinity Asset Advisors, LLC 22 Jan 2026
FBRX Forte Biosciences, Inc. Common Stock, par value $0.001 per share 6.7% $22,251,791 -$731,169 834,964 -3.2% Affinity Asset Advisors, LLC 22 Jan 2026
AVTX Avalo Therapeutics, Inc. Common Stock, $0.001 par value per share 5.7% $19,087,141 +$814,240 1,051,054 +4.5% Affinity Asset Advisors, LLC 22 Jan 2026
VRCA Verrica Pharmaceuticals Inc. Common Stock, $0.0001 par value per share 5.5% $7,346,762 884,172 0% Affinity Asset Advisors, LLC 22 Jan 2026
INZY Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share 2.9% $2,203,898 1,867,710 Affinity Healthcare Fund, LP 20 May 2025

Schedules 13D/G Reported by Affinity Asset Advisors, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.